Organovo Corp (ONVO) - מקדם חוב לטווח ארוך להון

The price characteristic on the GURU.Markets platform, which stands at 1.50, is driven by Organovo Holdings, Inc. (ONVO) partnerships with pharmaceutical laboratories for drug testing and the slow commercialization of 3D tissue printing. Current investor skepticism stems from a long capital payback period, although the business relies on the creation of bioprinted organs for liver therapy and deep research into molecular metabolism.

This metric evaluates the financing structure by comparing liabilities with maturities exceeding one year against equity. It determines the degree of financial stability and the risk of over-leverage. For Organovo Holdings, Inc. (ONVO), this balance is critical when scaling its bioprinting ecosystem and developing tools for pharma behemoths. By analyzing the current long-term debt-to-equity ratio on GURU.Markets, an investor can track the dynamics of the debt load, allowing for a balance between asset protection and growth potential.